AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior

Jonathan B. Rosenberg, Martin J. Hicks, Bishnu P. De, Odelya Pagovich, Esther Frenk, Kim D. Janda, Sunmee Wee, George F. Koob, Neil R. Hackett, Stephen M. Kaminsky, Stefan Worgall, Nicole Tignor, Jason G. Mezey, Ronald Crystal

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Cocaine addiction is a major problem affecting all societal and economic classes for which there is no effective therapy. We hypothesized an effective anti-cocaine vaccine could be developed by using an adeno-associated virus (AAV) gene transfer vector as the delivery vehicle to persistently express an anti-cocaine monoclonal antibody in vivo, which would sequester cocaine in the blood, preventing access to cognate receptors in the brain. To accomplish this, we constructed AAVrh.10antiCoc.Mab, an AAVrh.10 gene transfer vector expressing the heavy and light chains of the high affinity anti-cocaine monoclonal antibody GNC92H2. Intravenous administration of AAVrh.10antiCoc.Mab to mice mediated high, persistent serum levels of high-affinity, cocaine-specific antibodies that sequestered intravenously administered cocaine in the blood. With repeated intravenous cocaine challenge, naive mice exhibited hyperactivity, while the AAVrh.10antiCoc.Mab-vaccinated mice were completely resistant to the cocaine. These observations demonstrate a novel strategy for cocaine addiction by requiring only a single administration of an AAV vector mediating persistent, systemic anti-cocaine passive immunity.

Original languageEnglish
Pages (from-to)451-459
Number of pages9
JournalHuman Gene Therapy
Volume23
Issue number5
DOIs
Publication statusPublished - 1 May 2012
Externally publishedYes

Fingerprint

Passive Immunization
Cocaine
Anti-Idiotypic Antibodies
Cocaine-Related Disorders
Dependovirus
Monoclonal Antibodies
Intravenous Administration
Genes
Immunity
Vaccines
Economics
Light
Antibodies
Brain

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. / Rosenberg, Jonathan B.; Hicks, Martin J.; De, Bishnu P.; Pagovich, Odelya; Frenk, Esther; Janda, Kim D.; Wee, Sunmee; Koob, George F.; Hackett, Neil R.; Kaminsky, Stephen M.; Worgall, Stefan; Tignor, Nicole; Mezey, Jason G.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 23, No. 5, 01.05.2012, p. 451-459.

Research output: Contribution to journalArticle

Rosenberg, JB, Hicks, MJ, De, BP, Pagovich, O, Frenk, E, Janda, KD, Wee, S, Koob, GF, Hackett, NR, Kaminsky, SM, Worgall, S, Tignor, N, Mezey, JG & Crystal, R 2012, 'AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior', Human Gene Therapy, vol. 23, no. 5, pp. 451-459. https://doi.org/10.1089/hum.2011.178
Rosenberg, Jonathan B. ; Hicks, Martin J. ; De, Bishnu P. ; Pagovich, Odelya ; Frenk, Esther ; Janda, Kim D. ; Wee, Sunmee ; Koob, George F. ; Hackett, Neil R. ; Kaminsky, Stephen M. ; Worgall, Stefan ; Tignor, Nicole ; Mezey, Jason G. ; Crystal, Ronald. / AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. In: Human Gene Therapy. 2012 ; Vol. 23, No. 5. pp. 451-459.
@article{8101de33849649668f72a1f85dd18b61,
title = "AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior",
abstract = "Cocaine addiction is a major problem affecting all societal and economic classes for which there is no effective therapy. We hypothesized an effective anti-cocaine vaccine could be developed by using an adeno-associated virus (AAV) gene transfer vector as the delivery vehicle to persistently express an anti-cocaine monoclonal antibody in vivo, which would sequester cocaine in the blood, preventing access to cognate receptors in the brain. To accomplish this, we constructed AAVrh.10antiCoc.Mab, an AAVrh.10 gene transfer vector expressing the heavy and light chains of the high affinity anti-cocaine monoclonal antibody GNC92H2. Intravenous administration of AAVrh.10antiCoc.Mab to mice mediated high, persistent serum levels of high-affinity, cocaine-specific antibodies that sequestered intravenously administered cocaine in the blood. With repeated intravenous cocaine challenge, naive mice exhibited hyperactivity, while the AAVrh.10antiCoc.Mab-vaccinated mice were completely resistant to the cocaine. These observations demonstrate a novel strategy for cocaine addiction by requiring only a single administration of an AAV vector mediating persistent, systemic anti-cocaine passive immunity.",
author = "Rosenberg, {Jonathan B.} and Hicks, {Martin J.} and De, {Bishnu P.} and Odelya Pagovich and Esther Frenk and Janda, {Kim D.} and Sunmee Wee and Koob, {George F.} and Hackett, {Neil R.} and Kaminsky, {Stephen M.} and Stefan Worgall and Nicole Tignor and Mezey, {Jason G.} and Ronald Crystal",
year = "2012",
month = "5",
day = "1",
doi = "10.1089/hum.2011.178",
language = "English",
volume = "23",
pages = "451--459",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior

AU - Rosenberg, Jonathan B.

AU - Hicks, Martin J.

AU - De, Bishnu P.

AU - Pagovich, Odelya

AU - Frenk, Esther

AU - Janda, Kim D.

AU - Wee, Sunmee

AU - Koob, George F.

AU - Hackett, Neil R.

AU - Kaminsky, Stephen M.

AU - Worgall, Stefan

AU - Tignor, Nicole

AU - Mezey, Jason G.

AU - Crystal, Ronald

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Cocaine addiction is a major problem affecting all societal and economic classes for which there is no effective therapy. We hypothesized an effective anti-cocaine vaccine could be developed by using an adeno-associated virus (AAV) gene transfer vector as the delivery vehicle to persistently express an anti-cocaine monoclonal antibody in vivo, which would sequester cocaine in the blood, preventing access to cognate receptors in the brain. To accomplish this, we constructed AAVrh.10antiCoc.Mab, an AAVrh.10 gene transfer vector expressing the heavy and light chains of the high affinity anti-cocaine monoclonal antibody GNC92H2. Intravenous administration of AAVrh.10antiCoc.Mab to mice mediated high, persistent serum levels of high-affinity, cocaine-specific antibodies that sequestered intravenously administered cocaine in the blood. With repeated intravenous cocaine challenge, naive mice exhibited hyperactivity, while the AAVrh.10antiCoc.Mab-vaccinated mice were completely resistant to the cocaine. These observations demonstrate a novel strategy for cocaine addiction by requiring only a single administration of an AAV vector mediating persistent, systemic anti-cocaine passive immunity.

AB - Cocaine addiction is a major problem affecting all societal and economic classes for which there is no effective therapy. We hypothesized an effective anti-cocaine vaccine could be developed by using an adeno-associated virus (AAV) gene transfer vector as the delivery vehicle to persistently express an anti-cocaine monoclonal antibody in vivo, which would sequester cocaine in the blood, preventing access to cognate receptors in the brain. To accomplish this, we constructed AAVrh.10antiCoc.Mab, an AAVrh.10 gene transfer vector expressing the heavy and light chains of the high affinity anti-cocaine monoclonal antibody GNC92H2. Intravenous administration of AAVrh.10antiCoc.Mab to mice mediated high, persistent serum levels of high-affinity, cocaine-specific antibodies that sequestered intravenously administered cocaine in the blood. With repeated intravenous cocaine challenge, naive mice exhibited hyperactivity, while the AAVrh.10antiCoc.Mab-vaccinated mice were completely resistant to the cocaine. These observations demonstrate a novel strategy for cocaine addiction by requiring only a single administration of an AAV vector mediating persistent, systemic anti-cocaine passive immunity.

UR - http://www.scopus.com/inward/record.url?scp=84861664392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861664392&partnerID=8YFLogxK

U2 - 10.1089/hum.2011.178

DO - 10.1089/hum.2011.178

M3 - Article

C2 - 22486244

AN - SCOPUS:84861664392

VL - 23

SP - 451

EP - 459

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 5

ER -